Base de dados : HANSEN
Pesquisa : MINOCICLINA/IMUNOL [Descritor de assunto]
Referências encontradas : 1 [refinar]
Mostrando: 1 .. 1   no formato [Detalhado]

página 1 de 1

  1 / 1 HANSEN  
             
seleciona
para imprimir
Texto Completo-en
Id:27041
Autor:Fajardo, Tranquilino T Jr; Villahermos, Laarni G; Cruz, Eduardo C. Dela; Abalos, Rodolfo M; Franzblau, Scoott G; Walsh, Gerald P.
Título:Minocycline in Lepromatous Leprosy.
Fonte:Int. J. Lepr;63(1):8-17, 1995. ^btab.
Resumo:Twelve patients were treated with three dose levels of minocycline for 30 days, primarily to detect the dose-related effects on Mycobacterium leprae viability, followed by another 5 months of daily minocycline for overall efficacy and persistence of clinical and antibacterial effects. Subsequently, the patients were given standard WHO/MDT chemotherapy for multibacillary leprosy. Clinical improvement was recognizable during the first month, occurring much earlier among those on minocycline 200 mg daily than those who received minocycline 100 mg daily. A similar change also was observed in one patient 11 days after three daily doses of 100 mg of minocycline. At the end of 6 months, all patients were clinically improved with a slight reduction in the average bacterial index (BI) and logarithmic index of bacilli in biopsy (LIB). The effects of minocycline on viability by mouse foot pad inoculation and palmitic acid oxidation assays were noted beginning at 10 to 14 days of daily dosing and becoming more definite after 30 days of treatment. Both tests correlated fairly well. Doses of 200 mg daily did not appear to be more efficient than minocycline 100 daily. Phenolic glycolipid-I (PGL-I) antigen determinations done on some patients during the first month remained positive and did not correlate with changes in viability results. At the end of 6 months, after 5 months of 100 mg of minocycline monotherapy, no viable organisms could be demonstrated by mouse foot pad inoculation and palmitic acid oxidation assays; assays for PGL-I antigen were all negative.
Descritores:Hanseníase Virchowiana/imunol
Hanseníase Virchowiana/fisiopatol
Minociclina/imunol
Limites:Humanos
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1995/pdf/v63n1/v63n1a02.pdf - en.
Localização:BR191.1



página 1 de 1
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information